newsfilter
← Latest News
GlobeNewswire·

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring